Targeting Stress-Adaptive States: An Emerging Framework in Cancer Pharmacology.
Abstract
The failure of cancer therapy is largely driven by the remarkable capacity of tumor cells to adapt to pharmacological stress. Beyond genetic alterations and signaling pathway rewiring, malignant cells exploit dynamic stress-adaptive protein states that promote survival under cytotoxic conditions. Rather than providing a descriptive summary of the emerging literature, this review offers a critical analysis of the evidence supporting these adaptive states as therapeutic vulnerabilities. We evaluate the mechanistic basis, experimental limitations, and translational potential of non-canonical drug targets, including ribosomal specialization, translational reprogramming, phase-separated biomolecular condensates, and proteostasis buffering systems. By integrating insights from translational control, protein homeostasis, and stress biology, we critically assess current pharmacological strategies aimed at disrupting adaptive buffering capacity in cancer cells and identify the key challenges that must be overcome for clinical translation. We propose that quantifying stress-adaptive cellular states, rather than focusing solely on individual oncogenic proteins, offers a complementary extension of current frameworks - including drug-tolerant persister biology, non-oncogene addiction, and phenotypic plasticity - with the potential to delay or prevent therapy resistance. This perspective broadens the concept of druggable targets and highlights stress-adaptive protein states as an underexplored frontier for the development of more durable cancer therapies.